ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer

Anna-Lena Geißler, M Geissler, Daniel Kottmann, Lisa Lutz, Christiane D. Fichter, Ralph Fritsch, Britta Weddeling, Frank Makowiec, Martin Werner, Silke LaßmannOncotarget 2017 · DOI

TL;DR

This study identifies ATM mutations and low E-cadherin expression as potential new biomarkers for predicting response to EGFR-targeted therapies in colorectal cancer (CRC). These findings offer a more nuanced approach to patient stratification beyond current RAS mutation testing, potentially improving treatment outcomes for a significant subset of CRC patients.

What Problem Does This Paper Address?

EGFR-targeted therapies like Cetuximab and Panitumumab are crucial for treating RAS wildtype metastatic colorectal cancer (CRC). However, a substantial portion of these patients exhibit resistance, and current predictive markers, primarily RAS mutation status, are insufficient for effective patient stratification. This leaves a critical unmet need for additional biomarkers that can better identify who will benefit from these therapies and who might experience treatment failure. The authors aim to uncover novel molecular markers that can predict response or resistance to EGFR-targeted therapy in CRC.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: Seven CRC cell lines with known RAS mutation statuses were treated with Cetuximab. Their response was assessed using cell viability assays and antibody-dependent cellular cytotoxicity (ADCC).
  • Molecular profiling of cell lines: These cell lines underwent next-generation sequencing (NGS) to analyze mutations in a panel of 46 genes related to cancer pathways, including EGFR, RAS/MAPK, and PI3K/AKT. EGFR promoter methylation, mRNA, and protein expression were also evaluated. E-cadherin expression was assessed via immunofluorescence and Western blotting.
  • In situ studies: Tissue specimens from 25 CRC patients who received EGFR-targeted therapy were analyzed. This included primary tumors, recurrent tumors, and metastases. Similar molecular analyses (EGFR and E-cadherin expression, promoter methylation, MSI, CIMP status) were performed.
  • Functional validation: E-cadherin was experimentally downregulated in a Cetuximab-sensitive cell line (DLD1) using siRNA to assess its impact on treatment response.

Datasets

The study utilized two main datasets:

  • CRC Cell Lines: Seven established human colorectal cancer cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) were used for in vitro experiments.
  • CRC Patient Cohort: Tissue specimens from 25 colorectal cancer patients who received EGFR-targeted therapy (Cetuximab and/or Panitumumab) were analyzed. This cohort included primary tumors (24/25), recurrent tumors (1/25), and distant liver or lung metastases (20/25).

Key Insights and Ideas

  • RAS status is not the whole story: The study reinforces that RAS mutation status alone is insufficient to predict Cetuximab response, as both RAS wildtype and mutated cell lines showed variable responses.
  • EGFR expression and methylation are not reliable predictors: Contrary to some expectations, EGFR promoter methylation and EGFR protein expression levels did not consistently correlate with treatment response in either cell lines or patient samples.
  • ATM mutations emerge as a resistance marker: A significant finding is the association of ATM mutations with non-response to EGFR-targeted therapy in both cell lines and patient samples.
  • E-cadherin's critical role: Low E-cadherin expression was strongly linked to non-response. Crucially, experimentally reducing E-cadherin in a responsive cell line abrogated its sensitivity to Cetuximab, highlighting its functional importance.
  • PIK3CA exon 9 mutations may indicate sensitivity: Conversely, PIK3CA exon 9 mutations were observed in responsive cell lines and patients, suggesting a potential role in sensitivity.

Key Results

  • Cell line responses varied: Cetuximab elicited differential antibody-dependent cellular cytotoxicity (ADCC) in the seven CRC cell lines, with no direct link to RAS mutation status.
  • ATM mutations linked to non-response: Resistant cell lines (RKO, SW480) harbored ATM mutations, and this association was also observed in the patient cohort.
  • Low E-cadherin predicts non-response: Non-responding cell lines and patients generally displayed low E-cadherin expression.
  • E-cadherin knockdown abrogates response: Down-regulating E-cadherin in Cetuximab-sensitive DLD1 cells significantly impaired their ADCC response.
  • PIK3CA exon 9 mutations associated with response: Responding cell lines and patients often carried PIK3CA exon 9 mutations.
  • EGFR expression/methylation not predictive: In situ analyses confirmed that EGFR promoter methylation and expression levels did not reliably predict treatment outcomes.
  • ATM and E-cadherin as supportive markers: The study concludes that ATM mutations and E-cadherin expression are potential novel supportive predictive markers for EGFR-targeted therapy.

Limitations and Future Work

  • Retrospective nature: The patient cohort study was retrospective, which can introduce biases.
  • Limited sample size for specific analyses: While 25 patients were analyzed, specific molecular correlations might benefit from larger cohorts.
  • Mechanism of ATM's role: The precise functional consequences of ATM mutations in the context of EGFR pathway inhibition require further elucidation.
  • Soluble E-cadherin role: While the study observed E-cadherin expression patterns, the direct role of soluble E-cadherin in activating EGFR and conferring resistance was not definitively proven in this study, though it remains a strong hypothesis.
  • Future Directions: The authors suggest that ATM mutations and E-cadherin expression should be further investigated as supportive predictive markers to refine patient stratification for EGFR-targeted therapies. This could lead to more personalized treatment strategies in CRC.

Summary updated

Abstract

EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylation and EGFR expression as well as the MSI and or CIMP-type status did not guide treatment responses. In fact, EGFR-targeted treatment responses were also observed in RAS exon 2 p.G13 mutated CRC cell lines or CRC cases and were further linked to PIK3CA exon 9 mutations. In contrast, non-response to EGFR-targeted treatment was associated with ATM mutations and low E-cadherin expression. Moreover, down-regulation of E-cadherin by siRNA in otherwise Cetuximab responding E-cadherin positive cells abrogated their response. Hence, we here identify ATM and E-cadherin expression as potential novel supportive predictive markers for EGFR-targeted therapy.
BibTeX
@inproceedings{geiler2017atm,
  author = {Anna-Lena Geißler and M Geissler and Daniel Kottmann and Lisa Lutz and Christiane D. Fichter and Ralph Fritsch and Britta Weddeling and Frank Makowiec and Martin Werner and Silke Laßmann},
  title = {{ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer}},
  booktitle = {Oncotarget},
  year = {2017},
  doi = {10.18632/oncotarget.15211},
}
Figure